[go: up one dir, main page]

EP1210109A2 - Utilisation d'au moins un inhibiteur d'aminopeptidase - Google Patents

Utilisation d'au moins un inhibiteur d'aminopeptidase

Info

Publication number
EP1210109A2
EP1210109A2 EP01911521A EP01911521A EP1210109A2 EP 1210109 A2 EP1210109 A2 EP 1210109A2 EP 01911521 A EP01911521 A EP 01911521A EP 01911521 A EP01911521 A EP 01911521A EP 1210109 A2 EP1210109 A2 EP 1210109A2
Authority
EP
European Patent Office
Prior art keywords
inhibitor
tumor
immune cells
aminopeptidase
detected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP01911521A
Other languages
German (de)
English (en)
Inventor
Walter Schubert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MPB Meltec Patent und Beteiligungs GmbH
Original Assignee
Meltec Multi-Epitope-Ligand-Technologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meltec Multi-Epitope-Ligand-Technologies GmbH filed Critical Meltec Multi-Epitope-Ligand-Technologies GmbH
Priority to EP04024180A priority Critical patent/EP1510219A1/fr
Publication of EP1210109A2 publication Critical patent/EP1210109A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system

Definitions

  • the present invention relates to the use of at least one aminopeptidase inhibitor for the manufacture of a medicament for the treatment of tumor diseases and / or immune diseases, a corresponding pharmaceutical preparation, a method for identifying at least one aminopeptidase inhibitor and a method for identifying at least one further inhibitor which works in combination with the at least one aminopeptidase inhibitor.
  • Aminopeptidases are cell surface enzymes that cleave peptides. They are expressed by different cell types. Their molecular function consists, among other things, in the degradation of biologically active peptides. The further physiological, in particular the cellular functions of the aminopeptidases have not yet been clarified. Recent studies show that aminopeptidase inhibitors can suppress the rate of proliferation and invasion of tumor cells. This suppression of the invasion was generally attributed to the proteolytic activity of cell surface associated aminopeptidases, which cleave the extracellular matrix proteins so that the tumor cells can penetrate into organs and migrate in these organs.
  • Known aminopeptidase inhibitors include actinonin, bestatin, and potent homophthalimide-type inhibitors. Bestatin can be according to J.
  • a particular disadvantage is the fact that the previously existing investigation methods do not reflect the conditions in vivo and therefore often lead to unsatisfactory results, so that the action of the individual aminopeptidase inhibitors cannot be fully elucidated. It remains mostly unclear whether the inhibition of aminopeptidases in tumors in vivo, i.e. on the patient, is effective and whether an adverse effect, consisting in potentiating the invasive behavior in vivo, could not even occur in the case of certain types of tumor by inhibiting the aminopeptidases.
  • the mechanism of action of the aminopeptidase inhibitors with a known effect is completely unknown, so that no new substances can be developed or identified which can only have an extremely specific effect because they affect the cell functions in a known manner. For example, it has not yet been clarified with which other protein interactions occur in the same cell and how these interactions encode complex cell functions. It is therefore also not known whether and which cellular mechanisms that are based on such interactions can be specifically blocked by inhibiting the aminopeptidases, and which new indications result from the clinical use of such inhibitors or from these inhibitors further developed substances could result.
  • One of the objects is achieved by using at least one aminopeptidase inhibitor for the manufacture of a medicament for the treatment of tumor diseases and / or immune diseases, the at least one aminopeptidase inhibitor blocking polarization of invasive human or animal tumor and / or immune cells by modifying at least one surface protein CD13 as a member of a protein network on the surface of the tumor and / or immune cells, the protein network comprising up to 30 surface proteins from a group
  • CD4 1. CD4 2. CD8 3. HLA-DR 4. HLA-DQ 5. CD3
  • CD26 7. CD38 8. CD45RA 9. CD16 10. CD57
  • CD56 12. CD7 13. CD54 14. CD58 15. CD138 16. CD13 17. CD62L 18. CD71 19. CD11b 20. CD36
  • CD2 27. CD20 28. CD10 29. CD44 30. CD80 includes.
  • aminopeptidases control cell surface proteins which do not belong to the class of proteolytic enzymes but to the class of adhesion molecules, these adhesion molecules in a certain combination and spatial Arrangement are crucial for the polarization of the cells.
  • Aminopeptidases are superordinate control proteins in a protein network consisting of up to 30 different protein species on the cell surface, which control the polarization of tumor cells and of other invasive cells, such as immune cells, through targeted interaction with one another and which are listed above.
  • the inhibition of at least one aminopeptidase leads to a reproducible change in surface protein combinations on the cell surface, which always also includes a change in CD13.
  • polarization is to be understood as a process in which a primarily spherical cell changes into an elongated, elongated cell shape via various intermediate stages. This process, which is a shape change controlled by the complex protein network, is the prerequisite for cell migration, i.e. migration, since only cells with an elongated cell shape can migrate. The process of polarization is therefore imperative to all processes of cell migration and thus also to invasion.
  • the invention is based on the knowledge that it is precisely the aminopeptidase inhibitors which alter at least the surface proteins CD13, as a member of the specific protein network defined above, of up to 30 surface proteins, specifically inhibit the first and therefore most important step of the invasion and are therefore used to produce an extremely specific and therefore extremely effective drug for the treatment of tumor diseases and / or immune diseases can be.
  • the at least one aminopeptidase inhibitor can be, for example, an aminopeptidase inhibitor of the homophthalimide type and / or actinonin and / or bestatin and / or an antibody, in particular a monoclonal antibody, against one of the surface proteins. Bestatin in particular counteracts the assumptions set out above by the mechanism of action mentioned and leads to a change in the surface proteins of the protein network which comprises proteins from the group mentioned above. Actinonin, RB 3014 and a monoclonal antibody (clone SJ1 D1) directed against an extracellular domain of CD13 have also proven to be particularly effective.
  • aminopeptidase inhibitors specified above can be used to effectively prevent the polarization of tumor cells as well as the polarization of immune cells, the use of aminopeptidase inhibitors enables effective medicinal products to be used to treat autoimmune diseases or rejection reactions of transplanted organs or allergies, in particular allergies to the respiratory tract , to be provided.
  • At least one further inhibitor can be used to manufacture the medicinal product, which inhibits and / or modifies at least one surface protein that is not an aminopeptidase.
  • inhibition is to be understood as the general inhibition of the function of the at least one surface protein, which can also take place through a change in expression.
  • the blocking of the polarization can be increased enormously by using an inhibitor combination.
  • an antibody against CD45RA can be used as another Inhibitor. This inhibitor in particular enhances the action of an aminopeptidase inhibitor as defined above, so that the polarization can be specifically and particularly effectively inhibited by this inhibitor combination.
  • At least one aminopeptidase inhibitor and / or at least one further inhibitor can, in particular in addition to the change in CD13, bring about a change in at least one further surface protein of the tumor and / or immune cells, which affects adhesion to endothelial cells and / or extracellular structures, in particular to organ-specific ones Endothelial cells and / or to organ-specific extracellular structures.
  • At least one aminopeptidase inhibitor and / or at least one further inhibitor can also cause a change in the adhesive functions of endothelial cells. In this way it can be prevented that the tumor and / or immune cells bind to the endothelial cells, which is essential for polarization.
  • those aminopeptidase inhibitors or those further inhibitors can be used which specifically block the binding to the organ-specific endothelial cells and / or the organ-specific extracellular structures.
  • At least one surface protein in particular an adhesion molecule
  • at least one aminopeptidase inhibitor can be influenced by at least one aminopeptidase inhibitor and / or by at least one further inhibitor.
  • a pharmaceutical preparation which can be produced using at least one aminopeptidase inhibitor and / or a combination of at least one aminopeptidase inhibitor and at least one further inhibitor as described above. Furthermore, one of the tasks listed is achieved by a method for identifying aminopeptidase inhibitors which block the polarization of invasive human or animal tumor and / or immune cells, the method first detecting surface protein combinations of a protein network which are on the surface of the untreated tumor and / or immune cells, the protein network consisting of up to 30 surface proteins from a group
  • CD4 1. CD4 2. CD8 3. HLA-DR 4. HLA-DQ 5. CD3
  • CD26 7. CD38 8. CD45RA 9. CD16 10. CD57
  • CD56 12. CD7 13. CD54 14. CD58 15. CD138
  • CD13 17. CD62L 18. CD71 19. CD11b 20. CD36
  • CD2 27.
  • CD20 28.
  • CD10 29.
  • the or similar tumor and / or immune cells are treated with at least one aminopeptidase inhibitor.
  • the surface protein combinations of the protein network that are located on the surface of the treated tumor and / or immune cells are then detected and compared with the surface protein combinations of the protein network that are located on the surface of the untreated tumor and / or immune cells.
  • the at least one aminopeptidase inhibitor causes the polarization of the tumor and / or immune cells to be blocked.
  • the at least one identified aminopeptidase inhibitor can be added to at least one polarizing tumor and / or immune cell and the further development of the at least one polarizing tumor and / or immune cell can be detected in order to demonstrate the actual blocking of the polarization.
  • the method can further comprise a control step in which the binding of the untreated tumor and / or immune cells to organ-specific endothelial cells and / or to organ-specific extracellular structures is detected, the binding of the tumor cells treated with the at least one identified aminopeptidase inhibitor / or immune cells to the organ-specific endothelial cells and / or the organ-specific extracellular structures is detected and the detected bonds are compared. If a reduced binding is found in the treated tumor and / or immune cells, the polarization is inhibited particularly effectively, since an effective organ-specific adhesion is prevented.
  • One of the above objects is achieved by a method for the identification of inhibitors which, in combination with at least one aminopeptidase inhibitor, block the polarization of invasive human or animal tumor and / or immune cells, in the method first of all surface protein combinations of a protein network which are located on the surface of the untreated tumor and / or immune cells can be detected, the protein network comprising up to 30 surface proteins from a group whose composition has already been listed above.
  • the or similar tumor and / or immune cells are treated with at least one potential inhibitor and the surface protein combinations of the protein network that are on the surface of the treated tumor and / or immune cells are detected.
  • the detected surface protein combinations are then compared, the at least one inhibitor being suitable for blocking the polarization of the tumor and / or immune cells in the event of a deviation due to at least one change in a surface protein.
  • the tumor and / or immune cells of the same type can also be treated with at least one aminopeptidase inhibitor, the combination of the at least one Inhibitor and the at least one aminopeptidase inhibitor in the event of a deviation of the surface protein combinations detected in the two different steps by at least one change in a surface protein CD13 causes the blocking of the polarization of the tumor and / or immune cells.
  • the method can also include a further step in which the at least one identified inhibitor or a combination of the at least one identified inhibitor and the at least one aminopeptide inhibitor is added to at least one polarizing tumor and / or immune cell and further development the at least one polarizing tumor and / or immune cell is detected.
  • the method can advantageously include a control step in which the binding of the untreated tumor and / or immune cells to organ-specific endothelial cells and / or to organ-specific extracellular structures is detected, in which the binding with the at least one identified inhibitor and / or with a combination from the at least one identified inhibitor and the at least one aminopeptidase inhibitor-treated tumor and / or immune cells to the organ-specific endothelial cells and / or the organ-specific extracellular structures is detected and in which the detected bonds are compared.
  • the detection of the surface protein combinations can comprise procedural steps of an automated method for determining molecular classes, molecular groups or molecular parts in a solid or liquid object according to DE 197 09 348 C.
  • control steps listed check whether the polarization is prevented by the at least one aminopeptidase inhibitor and / or the at least one further inhibitor by inhibiting the binding of certain molecules to defined structures.
  • These control steps can be carried out by passing immune cells (lymphocytes) and / or tumor cells in the form of a continuous cell flow in a special device, which is described in DE 199 32 158 A, over at least one sample with the defined structures. While the cells should be bound to the defined structures without treatment with the at least one aminopeptidase inhibitor and / or the at least one further inhibitor, after treatment of the cells with the at least one aminopeptidase inhibitor and / or the at least one further inhibitor takes place no binding or a reduced binding to the structures.
  • the sample can consist, for example, of an organ tissue section.
  • the figure shows, in chronological order, photographs of polarizing cells, untreated and treated with a target inhibitor.
  • the 30 cell surface proteins already listed above could be identified that belong to a specific protein network that controls the early phases of the polarization of tumor cells and immune cells.
  • surface protein combinations of this protein network were untreated by Karpas cells and detected after treatment with the aminopeptidase inhibitor actinonin.
  • two groups V1 and V2 of Karpas cells were formed, the cells of group V1 not being treated, while the cells of group V2 being treated with actinonin.
  • Table 2 lists those surface protein combinations which occur both in the actinonin-treated and in the untreated cells. In this and the other tables 3 and 4, however, only 18 of the 30 proteins are listed by way of example, the detected proteins being identified by 1 and the non-detected proteins being identified by 0.
  • CD2 1. CD3 3. CD4 4. CD8 5. CD16 6. CD56
  • CD57 7. CD26 9. CD38 10. CD71 11. HLA-DR 12. HLA-DQ
  • CD11b 14. CD45RA 15. CD7 16. CD62L 17. CD36 18. CD19
  • Tables 2 to 4 relate to 1000 cells examined in groups V1 and V2.
  • Table 2 shows a total of 203 different protein combinations.
  • Table 3 lists the surface protein combinations that only occur in the untreated Karpas cells and are never found in the Actinonin-treated Karpas cells.
  • the number of protein combinations referred to in Table 3 is 131.
  • Table 4 finally lists those surface protein combinations which only occur in the actinonin-treated Karpas cells. Table 4 contains 60 different protein combinations.
  • Tables 2 to 4 show that when only 18 proteins of the 30 proteins are considered, a total of 394 different surface protein combinations occur, with a total of 334 different combinations being found in the untreated cells and a total of 263 different combinations being detected in the treated cells can.
  • the change in the surface protein combinations detected hereby leads to a specific blocking of the cell polarization.
  • Protein code 1 Proteins [1 - 18], binary number number in
  • Protein code binary code per line 181 1 0 1 1 0 0 1 1 0 1 0 1 0 1 0 1 0 1 1 1 0 0 0.1 0.2
  • Protein code 2 proteins [1 - 1 3], binary number number in
  • 1 protein code binary code per line 87 0 1 0 1 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0.1 0.0
  • Protein code 3 proteins [1 - 1 3], binary number number in
  • 1 protein code binary code per line 0 1 0 0 0 0 0 0 0 0 1 1 0 1 0 0 0 1 0 0 0.0 0.1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne l'utilisation d'au moins un inhibiteur d'aminopeptidase, afin de produire un médicament permettant le traitement de maladies tumorales et/ou de maladies immunitaires. Ledit inhibiteur d'aminopeptidase induit un blocage d'une polarisation de cellules tumorales et/ou immunitaires, humaines ou animales, invasives, par modification d'au moins une protéine de surface CD13, membre d'un réseau de protéines se trouvant à la surface des cellules tumorales et/ou immunitaires. Ledit réseau de protéines comprend jusqu'à 30 protéines de surface issues d'un groupe défini. La présente invention concerne également une préparation pharmaceutique, un procédé d'identification d'au moins un inhibiteur d'aminopeptidase, ainsi qu'un procédé d'identification d'au moins un autre inhibiteur, qui agit en combinaison avec ledit inhibiteur d'aminopeptidase.
EP01911521A 2000-01-24 2001-01-24 Utilisation d'au moins un inhibiteur d'aminopeptidase Ceased EP1210109A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04024180A EP1510219A1 (fr) 2000-01-24 2001-01-24 Méthode d'identification d'au moins un inhibiteur d'Aminopeptidase

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10002820A DE10002820A1 (de) 2000-01-24 2000-01-24 Aminopeptidasen-Inhibitor
DE10002820 2000-01-24
PCT/EP2001/000746 WO2001054707A2 (fr) 2000-01-24 2001-01-24 Utilisation d'au moins un inhibiteur d'aminopeptidase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP04024180A Division EP1510219A1 (fr) 2000-01-24 2001-01-24 Méthode d'identification d'au moins un inhibiteur d'Aminopeptidase

Publications (1)

Publication Number Publication Date
EP1210109A2 true EP1210109A2 (fr) 2002-06-05

Family

ID=7628482

Family Applications (2)

Application Number Title Priority Date Filing Date
EP04024180A Ceased EP1510219A1 (fr) 2000-01-24 2001-01-24 Méthode d'identification d'au moins un inhibiteur d'Aminopeptidase
EP01911521A Ceased EP1210109A2 (fr) 2000-01-24 2001-01-24 Utilisation d'au moins un inhibiteur d'aminopeptidase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP04024180A Ceased EP1510219A1 (fr) 2000-01-24 2001-01-24 Méthode d'identification d'au moins un inhibiteur d'Aminopeptidase

Country Status (7)

Country Link
US (2) US20030130180A1 (fr)
EP (2) EP1510219A1 (fr)
JP (1) JP2003520821A (fr)
CN (1) CN1358099A (fr)
DE (1) DE10002820A1 (fr)
SG (1) SG119168A1 (fr)
WO (1) WO2001054707A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
DE10330842A1 (de) * 2003-07-08 2005-02-10 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention dermatologischer Erkrankungen mit Hyperproliferation und veränderten Differenzierungszuständen von Fibroblasten
DE10337074A1 (de) 2003-08-12 2005-03-17 Keyneurotek Ag Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention von chronischen neurodegenerativen Erkrankungen
EP1722231A3 (fr) * 2005-04-27 2009-03-11 MPB MelTec Patent- und Beteiligungsgesellschaft mbH Méthode d'identification de cellules somatiques dérivées
US20070192884A1 (en) * 2006-01-25 2007-08-16 Daniel Chelsky TAT-038 and methods of assessing and treating cancer
GB0802009D0 (en) * 2008-02-04 2008-03-12 Chroma Therapeutics Ltd Biomarkers of aminopeptidase inhibition
GB0803076D0 (en) * 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
WO2014165573A1 (fr) * 2013-04-02 2014-10-09 University Of Connecticut Régulation du rejet du greffon de tissus et organes de donneurs et dérivés de cellules souches embryonnaires

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0167936A2 (fr) * 1984-07-03 1986-01-15 Microbial Chemistry Research Foundation Utilisation d'actinonine comme immunopotentiateur
WO1998044923A1 (fr) * 1997-04-10 1998-10-15 Sloan-Kettering Institute For Cancer Research Effets anti-neoplasiques de l'actinonine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS609487B2 (ja) * 1976-03-26 1985-03-11 財団法人微生物化学研究会 免疫制癌剤
GB1540019A (en) * 1977-06-01 1979-02-07 Microbial Chem Res Found Bestatin derivatives
US5670113A (en) * 1991-12-20 1997-09-23 Sibia Neurosciences, Inc. Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same
ES2157227T3 (es) * 1993-02-09 2001-08-16 Becton Dickinson Co Asignacion automatica del linaje de leucemias agudas mediante citometria de flujo.
US5817750A (en) * 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0167936A2 (fr) * 1984-07-03 1986-01-15 Microbial Chemistry Research Foundation Utilisation d'actinonine comme immunopotentiateur
WO1998044923A1 (fr) * 1997-04-10 1998-10-15 Sloan-Kettering Institute For Cancer Research Effets anti-neoplasiques de l'actinonine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAGECHIKA ET AL: "Potent homophthalimide-type inhibitors of B16F10/L5 mouse melanoma cell invasion", BIOLOGICAL PHARMACEUTICAL BULLETIN, vol. 22, no. 9, 1999, pages 1010 - 1012, XP000986267 *
LENDECKEL ET AL: "Inhibition of alanyl aminopeptidase induces MAP-kinase p42/ERK42 in the human T cell line KARPAS 299", BIOCHEMICAL BIOPHYSICAL RESEARCH, vol. 252, no. 1, 1998, pages 5 - 9, XP000999102 *
YAMAZAKI ET AL: "Effect of ubenimex on the immune system of patients with hematologic malignancies", BIOMEDICINE & PHARMACOTHERAPY, vol. 45, no. 2-3, 1991, pages 105 - 112, XP000999659 *

Also Published As

Publication number Publication date
WO2001054707A2 (fr) 2001-08-02
EP1510219A1 (fr) 2005-03-02
US20030130180A1 (en) 2003-07-10
SG119168A1 (en) 2006-02-28
JP2003520821A (ja) 2003-07-08
DE10002820A1 (de) 2001-08-23
WO2001054707A3 (fr) 2002-03-14
US20060263373A1 (en) 2006-11-23
CN1358099A (zh) 2002-07-10

Similar Documents

Publication Publication Date Title
Nirenberg et al. Modulation of synapse formation by cyclic adenosine monophosphate
DE69934120T2 (de) Inhibitoren der proteasomalen aktivität zur stimulierung des haarwuchses
DE69624239T2 (de) Fgfr3 als signal für die vorläufer der mesenchymzellen des skeletts
Cucchiaro et al. Electron‐microscopic analysis of synaptic input from the perigeniculate nucleus to the A‐laminae of the lateral geniculate nucleus in cats
Ulfhake et al. A quantitative light microscopic study of the dendrites of cat spinal γ‐motoneurons after intracellular staining with horseradish peroxidase
DE2512730C2 (de) Vorrichtung zum Durchführen immunologischer Nachweisreaktionen und Verfahren unter Verwendung einer solchen Vorrichtung
DE69524094T2 (de) Verwendung von isolierten domänen des typ-iv-kollagens zur modifikation von zell- und gewebeinteraktionen
Guillery Some electron microscopical observations of degenerative changes in central nervous synapses
Calvet Patterns of spontaneous electrical activity in tissue cultures of mammalian cerebral cortex vs. cerebellum
DE69030480T2 (de) Verfahren und Vorrichtung zum Nachweis sensibilisierter Leukozyten
DE2532779C3 (de) Verfahren zum elektroquantitativen Bestimmen von Proteinen
EP1210109A2 (fr) Utilisation d'au moins un inhibiteur d'aminopeptidase
Santer et al. A study of the distribution of chromaffin-positive (CH+) and small intensely fluorescent (SIF) cells in sympathetic ganglia of the rat at various ages
DE3850728T2 (de) Methode zur Bestimmung des Verhaltens von Medikamenten in Lebewesen.
DE69527289T2 (de) Verfahren und Vorrichtung zur Bestimmung der Fruchtarbarkeit von Spermatozoenproben
DE60023324T2 (de) Zusammensetzung zur in-vitro befruchtung
DE60117180T2 (de) Verfahren zur messung des aktivierungszustands von signalwegen in zellen
WO2003005023A2 (fr) Procede pour determiner des interactions entre des keratinocytes et des neurones
DE1598870A1 (de) Methode zur Blutgruppenbestimmung und Vorrichtung zur Durchfuehrung derselben
DE60010715T2 (de) Klinische kontrollmaterialien zu knochen-resorptions-markern
DE69735374T2 (de) Methode zur auffindung physiologisch aktiver substanzen und verfahren zu deren herstellung
DE2639180A1 (de) Verfahren zur herstellung einer endogenen, morphinaehnlichen verbindung und nach dem verfahren hergestellte verbindung
DE102006012613B4 (de) Verfahren zur Bestimmung der therapeutischen Wirksamkeit von Substanzen
EP1136823A2 (fr) Méthode pour l'identification et l'enrichissement des structures cibles spécifiques aux cellules
EP1309856A2 (fr) Utilisation d'un reseau d'electrodes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011016

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

17Q First examination report despatched

Effective date: 20040708

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MPB MELTEC PATENT- UND BETEILIGUNGSGESELLSCHAFT MB

RTI1 Title (correction)

Free format text: UTILIZATION OF AT LEAST ONE AMINOPEPTIDASE INHIBITOR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20071207